Welcome to our dedicated page for Kiniksa Pharmaceuticals International news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International stock.
Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals reported Q1 2022 net revenue of $22.2 million from ARCALYST, contributing to total revenues of $32.2 million. The company anticipates full-year net revenue from ARCALYST between $115 million and $130 million and expects cash reserves to sustain operations through 2024. Kiniksa's strategic collaboration with Huadong Medicine is expected to yield potential milestone payments up to $640 million. Despite a net loss of $25.2 million, this is an improvement from the previous year's loss of $49.5 million.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will hold a conference call on May 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q1 2022 financial results and corporate activities. A live webcast will be available on their website, with a replay accessible 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases, with a portfolio that includes ARCALYST®, vixarelimab, KPL-404, and mavrilimumab, targeting significant unmet medical needs through innovative biologic mechanisms.
Kiniksa Pharmaceuticals reported Q4 2021 net revenue of $18.7 million from ARCALYST, totaling $38.5 million for the full year. Profitability was achieved in Q4 2021. The company expects ARCALYST net revenue for 2022 to range from $115 million to $130 million. A strategic collaboration with Huadong Medicine is set to enhance the development of ARCALYST and mavrilimumab in the Asia Pacific. Kiniksa's Q4 2021 net loss narrowed to $36.3 million from $53.7 million year-over-year, while cash reserves stood at $182.2 million.
Kiniksa Pharmaceuticals (KNSA) announces a strategic collaboration with Huadong Medicine to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific region, excluding Japan. Kiniksa will receive $22 million upfront and could earn up to $640 million in milestone payments, alongside tiered royalties. This partnership aims to enhance access to treatments for severe autoimmune diseases, leveraging Huadong's regional expertise and resources.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will hold a conference call and live webcast on February 22, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2021 financial results and provide a corporate update. The event aims to inform investors and the public about the company's performance and strategies. A live webcast will be available on its website, with a replay accessible within 48 hours. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet needs, utilizing innovative assets like ARCALYST and mavrilimumab.
Kiniksa Pharmaceuticals (KNSA) provided a corporate update on January 10, 2022, highlighting significant milestones for 2022. The company noted a successful launch of ARCALYST for recurrent pericarditis, with strong adoption. Year-end cash reserves are approximately $182 million, enough to fund operations into 2024. Upcoming developments include Phase 2b data for vixarelimab in prurigo nodularis expected in 2H 2022 and KPL-404's Phase 2 trial in rheumatoid arthritis currently enrolling patients. The complete 2022 ARCALYST revenue guidance will be shared with Q4 2021 financial results.
Kiniksa Pharmaceuticals (KNSA) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. ET. A live webcast of the presentation will be available on Kiniksa's website, with replays accessible within 48 hours post-event. The firm focuses on developing therapeutic medicines for diseases with significant unmet needs, featuring assets like ARCALYST® and mavrilimumab. For more details, visit www.kiniksa.com.
Kiniksa Pharmaceuticals (KNSA) announced that the Phase 3 trial for its investigational drug mavrilimumab, targeting COVID-19-related acute respiratory syndrome (ARDS), failed to meet its primary efficacy endpoint. The trial involved 582 patients and aimed to assess mavrilimumab's effectiveness in hospitalized patients with severe COVID-19 pneumonia. Despite the disappointing results, Kiniksa remains optimistic about mavrilimumab's potential and plans to focus on its ARCALYST franchise and other drug development programs, including vixarelimab and KPL-404.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 12:10 p.m. ET. The presentation will be available via live webcast on Kiniksa’s website, with a replay accessible approximately 48 hours post-event. Kiniksa is focused on developing therapeutic medicines for patients with significant unmet medical needs, boasting a portfolio including ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, targeting various immunological conditions.
Kiniksa Pharmaceuticals reported Q3 2021 net revenue of $12.1 million from ARCALYST, with over 200 physicians prescribing the treatment for recurrent pericarditis. The company anticipates Phase 3 trial data for mavrilimumab in COVID-19-related ARDS in Q1 2022 and Phase 2b data for vixarelimab in prurigo nodularis in 2H 2022. Kiniksa forecasts Q4 2021 ARCALYST net revenue between $16.0 million and $17.0 million and projects sufficient cash to fund operations into 2023.